MEPSGEN Launches NanoCalibur™ in US: Advanced Microfluidic Platform for Scalable Nanoparticle Production
Key Insights
MEPSGEN (search) has introduced NanoCalibur (search)™ to the US market following successful deployment in Korea, offering researchers a platform for precise and reproducible nanoparticle synthesis with >95% encapsulation efficiency.
The system leverages patented microvortex-based mixing technology with closed-loop feedback control, enabling seamless scale-up from laboratory discovery to GMP production without protocol re-optimization.
Co-founded by YongTae Kim (search) and MIT's Robert Langer (search), MEPSGEN (search) aims to address critical challenges in nanoparticle production for mRNA (search) vaccines, gene therapies, and other advanced therapeutics.
MEPSGEN (search) US Inc. has announced the United States launch of NanoCalibur (search)™, an advanced microfluidic platform designed for scalable nanoparticle production. The system, which made its successful debut in Korea during Q4 2024, is now available to US researchers and drug developers seeking reliable and scalable methods for nanoparticle synthesis.
The NanoCalibur (search)™ platform employs sophisticated microfluidic technology that enables precise and reproducible synthesis of various nanoparticle types, including lipid nanoparticles (search) (LNPs), liposomes, and lipid-polymer hybrids. According to the company, the system's proprietary design maximizes payload encapsulation while maintaining structural integrity and biomolecular stability.
Addressing Critical Challenges in Nanoparticle Production
Nanoparticles have emerged as essential delivery vehicles for numerous therapeutic modalities, including mRNA (search) vaccines, non-viral gene therapies, oligonucleotide therapeutics, and chemotherapy agents. However, researchers frequently encounter difficulties in achieving consistent, controllable nanoparticle synthesis, particularly when working with sensitive payloads such as nucleic acids.
The NanoCalibur (search)™ system tackles these challenges through its patented microvortex-based mixing platform and closed-loop feedback control system. This configuration enables continuous throughput with high efficiency and low-shear production conditions, critical factors for preserving cargo integrity.
"We are thrilled to bring NanoCalibur (search)™, a stable, reliable and high-precision nanoparticle synthesis platform, to the U.S. market," said YongTae Kim (search), CEO of MEPSGEN (search). "With its cutting-edge microfluidics technology and user-friendly design, this micro-lab makes it easier for researchers to focus on their mission to develop the next generation of nanoparticle-based therapeutics."
Technical Performance and Scalability
Performance data shared by MEPSGEN (search) demonstrates the system's capability to consistently produce nanoparticles with impressive specifications:
- Polydispersity index (PDI) below 0.1
- Encapsulation efficiencies exceeding 95%, including for mRNA payloads
- Hydrodynamic stability maintained for over four weeks
- Preservation of mRNA integrity throughout the production process
A key advantage of the NanoCalibur (search)™ platform is its seamless scalability from laboratory discovery to GMP production environments. With mixing efficiency exceeding 95%, the system produces uniform nanoparticles with minimal batch-to-batch variation. The controlled shear rates are particularly beneficial for preserving the stability of sensitive biomolecules like mRNA (search), even at larger production scales.
This scalability eliminates the need for extensive protocol re-optimization when transitioning from research to production, potentially accelerating development timelines for nanoparticle-based therapeutics.
Upcoming Technology Showcase
As part of MEPSGEN (search)'s expansion in the US market, CEO YongTae Kim (search) will present the technology at the 4th LNP Formulation & Process Development Summit in Boston on April 15, 2025. His presentation, titled "Parallelization of microvortex mixers enables scalable manufacturing of mRNA (search)-LNPs while preventing mRNAs from being truncated under controlled shear rates," will take place during the Process Development & Manufacturing track.
Company Background
MEPSGEN (search) is a biotech company headquartered in Seoul, South Korea, with US offices in Cambridge, Massachusetts, and San Jose, California. The company was co-founded in 2019 by current CEO YongTae Kim (search) and Professor Robert Langer (search) from MIT, a renowned expert in drug delivery and biomaterials who has pioneered numerous breakthroughs in controlled-release systems.
Beyond the NanoCalibur (search)™ platform, MEPSGEN (search) also offers organ-on-a-chip technology, further expanding its contributions to drug development and personalized medicine. The company's focus on microfluidic technologies supports applications across drug discovery, preclinical research, and GMP manufacturing.
The US launch of NanoCalibur (search)™ represents a significant advancement in nanoparticle production technology, potentially accelerating the development of next-generation therapeutics that rely on precise nanoparticle delivery systems.